462 related articles for article (PubMed ID: 19877156)
1. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Zauli G; Rimondi E; Celeghini C; Milani D; Secchiero P
J Cell Physiol; 2010 Feb; 222(2):357-64. PubMed ID: 19877156
[TBL] [Abstract][Full Text] [Related]
2. Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclasts.
Rimondi E; Zweyer M; Ricci E; Fadda R; Secchiero P
Anat Rec (Hoboken); 2007 Jul; 290(7):838-45. PubMed ID: 17506059
[TBL] [Abstract][Full Text] [Related]
3. Genistein and zinc synergistically stimulate apoptotic cell death and suppress RANKL signaling-related gene expression in osteoclastic cells.
Uchiyama S; Yamaguchi M
J Cell Biochem; 2007 Jun; 101(3):529-42. PubMed ID: 17295206
[TBL] [Abstract][Full Text] [Related]
4. TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells.
Yen ML; Tsai HF; Wu YY; Hwa HL; Lee BH; Hsu PN
Mol Immunol; 2008 Apr; 45(8):2205-13. PubMed ID: 18206242
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
Morales JC; Ruiz-Magaña MJ; Carranza D; Ortiz-Ferrón G; Ruiz-Ruiz C
Cancer Lett; 2010 Nov; 297(1):91-100. PubMed ID: 20580868
[TBL] [Abstract][Full Text] [Related]
6. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P; Melloni E; Corallini F; Beltrami AP; Alviano F; Milani D; D'Aurizio F; di Iasio MG; Cesselli D; Bagnara GP; Zauli G
Stem Cells; 2008 Nov; 26(11):2955-63. PubMed ID: 18772312
[TBL] [Abstract][Full Text] [Related]
8. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
9. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
10. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia.
Moulin M; Dumontet C; Arrigo AP
Cancer Lett; 2007 May; 250(1):117-27. PubMed ID: 17141951
[TBL] [Abstract][Full Text] [Related]
12. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.
Zauli G; Rimondi E; Nicolin V; Melloni E; Celeghini C; Secchiero P
Blood; 2004 Oct; 104(7):2044-50. PubMed ID: 15213096
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances for research on anti-tumor effects of TNF-related apoptosis-inducing ligand].
Yao GH; Hou YY
Wei Sheng Yan Jiu; 2006 Jan; 35(1):115-7. PubMed ID: 16598953
[TBL] [Abstract][Full Text] [Related]
14. 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation.
Han H; Shin SW; Seo CY; Kwon HC; Han JY; Kim IH; Kwak JY; Park JI
Apoptosis; 2007 Nov; 12(11):2101-14. PubMed ID: 17786557
[TBL] [Abstract][Full Text] [Related]
15. Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers.
Hofmanová J; Vaculová A; Hyzd'alová M; Kozubík A
Oncol Rep; 2008 Feb; 19(2):567-73. PubMed ID: 18202809
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Iacomino G; Medici MC; Russo GL
Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
[TBL] [Abstract][Full Text] [Related]
17. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
19. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors.
Zauli G; Rimondi E; Stea S; Baruffaldi F; Stebel M; Zerbinati C; Corallini F; Secchiero P
J Cell Physiol; 2008 Jan; 214(1):117-25. PubMed ID: 17620297
[TBL] [Abstract][Full Text] [Related]
20. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
Secchiero P; Zauli G
Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
